Remove Circulation Remove Heart Failure Remove Preserved Ejection Fraction
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction

Circulation: Heart Failure

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010802, November 1, 2023. Heart failure with preserved ejection fraction (HFpEF) has become the leading form of heart failure worldwide, particularly among elderly patient populations.

article thumbnail

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

Circulation: Heart Failure

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.

article thumbnail

Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction

Circulation: Heart Failure

Circulation: Heart Failure, Ahead of Print. Background:NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures.

article thumbnail

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Circulation

Circulation, Volume 148, Issue 24 , Page 1945-1957, December 12, 2023. BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Controlled BP was defined as BP under threshold.

article thumbnail

Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials

Circulation

Circulation, Ahead of Print. BACKGROUND:Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. P=0.022) in favor of dapagliflozin. 95% CI, 0.00, 8.3;P=0.058). meters (95% CI, −6.5,

article thumbnail

Coronary Microvascular Dysfunction in Patients With Heart Failure: Characterization of Patterns in HFrEF Versus HFpEF

Circulation: Heart Failure

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Coronary microvascular dysfunction (CMD) is involved in heart failure (HF) onset and progression, independently of HF phenotype and obstructive coronary artery disease.